Park Avenue Securities’s Eli Lilly LLY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $42.7M | Buy |
35,602
+3,576
| +11% | +$3.65M | 0.27% | 62 |
|
|
2026
Q1 | $29.5M | Buy |
32,026
+3,913
| +14% | +$3.97M | 0.23% | 74 |
|
|
2025
Q4 | $30.2M | Buy |
28,113
+2,711
| +11% | +$2.59M | 0.26% | 63 |
|
|
2025
Q3 | $19.4M | Buy |
25,402
+1,502
| +6% | +$1.12M | 0.15% | 106 |
|
|
2025
Q2 | $18.6M | Buy |
23,900
+239
| +1% | +$186K | 0.17% | 99 |
|
|
2025
Q1 | $19.5M | Buy |
23,661
+4,387
| +23% | +$3.65M | 0.24% | 63 |
|
|
2024
Q4 | $14.9M | Buy |
19,274
+2,381
| +14% | +$1.97M | 0.15% | 100 |
|
|
2024
Q3 | $15M | Sell |
16,893
-1,705
| -9% | -$1.53M | 0.17% | 90 |
|
|
2024
Q2 | $16.8M | Buy |
18,598
+1,404
| +8% | +$1.12M | 0.21% | 75 |
|
|
2024
Q1 | $13.4M | Buy |
17,194
+1,985
| +13% | +$1.41M | 0.17% | 83 |
|
|
2023
Q4 | $8.87M | Buy |
15,209
+291
| +2% | +$170K | 0.12% | 111 |
|
|
2023
Q3 | $8.01M | Sell |
14,918
-1,618
| -10% | -$834K | 0.12% | 108 |
|
|
2023
Q2 | $7.75M | Buy |
16,536
+1,152
| +7% | +$483K | 0.12% | 112 |
|
|
2023
Q1 | $5.28M | Buy |
15,384
+3,623
| +31% | +$1.22M | 0.09% | 148 |
|
|
2022
Q4 | $4.3M | Buy |
11,761
+864
| +8% | +$306K | 0.08% | 169 |
|
|
2022
Q3 | $3.52M | Buy |
10,897
+1,390
| +15% | +$440K | 0.07% | 170 |
|
|
2022
Q2 | $3.08M | Buy |
9,507
+1,917
| +25% | +$575K | 0.06% | 194 |
|
|
2022
Q1 | $2.17M | Buy |
7,590
+1,020
| +16% | +$263K | 0.04% | 261 |
|
|
2021
Q4 | $1.81M | Buy |
6,570
+948
| +17% | +$240K | 0.03% | 296 |
|
|
2021
Q3 | $1.3M | Buy |
5,622
+394
| +8% | +$97.2K | 0.03% | 335 |
|
|
2021
Q2 | $1.2M | Buy |
5,228
+159
| +3% | +$31.9K | 0.03% | 331 |
|
|
2021
Q1 | $947K | Sell |
5,069
-22
| -0.4% | -$4.3K | 0.02% | 360 |
|
|
2020
Q4 | $860K | Buy |
5,091
+55
| +1% | +$8.21K | 0.02% | 326 |
|
|
2020
Q3 | $745K | Buy |
5,036
+59
| +1% | +$9.13K | 0.02% | 297 |
|
|
2020
Q2 | $817K | Buy |
+4,977
| New | +$764K | 0.03% | 230 |
|
|
2020
Q1 | – | Sell |
-4,871
| Closed | -$640K | – | 466 |
|
|
2019
Q4 | $640K | Buy |
4,871
+117
| +2% | +$13.6K | 0.03% | 248 |
|
|
2019
Q3 | $532K | Buy |
+4,754
| New | +$529K | 0.03% | 237 |
|
|
2019
Q2 | – | Sell |
-3,400
| Closed | -$439K | – | 376 |
|
|
2019
Q1 | $439K | Buy |
+3,400
| New | +$413K | 0.02% | 241 |
|
|
2017
Q3 | – | Sell |
-4,028
| Closed | -$332K | – | 186 |
|
|
2017
Q2 | $332K | Buy |
+4,028
| New | +$329K | 0.04% | 121 |
|
Other funds holding LLY
SC
ONB
GIM
Park Avenue Securities's LLY Position: Q2 2026 in Review
Park Avenue Securities increased its Eli Lilly (LLY) stake by 11% in Q2 2026, buying an estimated $3.65M and bringing the position to 35,602 shares worth $42.7M. The position accounts for 0.27% of the portfolio, ranked #62.
Park Avenue Securities first reported a position in LLY in Q2 2017 and has held it in 29 quarters since. 1,558 funds tracked by Wall St. Rank hold LLY as of Q2 2026.
- Park Avenue Securities held 35,602 shares of Eli Lilly worth $42.7M as of Q2 2026.
- Park Avenue Securities bought 3,576 Eli Lilly shares in Q2 2026, an estimated $3.65M.
- Eli Lilly made up 0.27% of Park Avenue Securities's portfolio in Q2 2026, its #62 holding.
- Park Avenue Securities first reported a position in Eli Lilly in Q2 2017 and has held it in 29 quarters since.
- 1,558 funds tracked by Wall St. Rank held Eli Lilly as of Q2 2026.
Based on Park Avenue Securities's 13F filing for Q2 2026, filed 20 Jul 2026.